医药行业周报：本周申万医药生物指数下跌2.8%，关注原料药价格反转趋势-20260322

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical industry, indicating a positive outlook compared to the overall market performance [2][38]. Core Insights - The pharmaceutical sector experienced a decline of 2.8% this week, with the overall market indices also showing negative trends. The pharmaceutical index ranked 8th among 31 sub-industries [2][3]. - Recent fluctuations in chemical raw material prices have led to a reversal in prices for many active pharmaceutical ingredients (APIs) and intermediates, suggesting potential investment opportunities [12]. - Significant advancements in drug development were noted, including successful clinical trials for Pfizer's CDK4 inhibitor and other innovative treatments [17][21][23]. Market Performance - The pharmaceutical index fell by 2.8%, while the Shanghai Composite Index decreased by 3.4% and the Wind All A Index (excluding financials and petrochemicals) dropped by 4.5% [2][3]. - The overall valuation of the pharmaceutical sector stands at 29.5 times earnings, ranking 11th among 31 primary industries [6][16]. Recent Key Events - Pfizer's CDK4 inhibitor showed positive results in a Phase II trial for advanced breast cancer, significantly improving progression-free survival (PFS) [17]. - The KX-826 solution from 开拓药业 reached its primary endpoint in a Phase III trial for androgenetic alopecia, demonstrating a notable increase in hair count compared to the placebo group [21]. - Johnson & Johnson's Icotrokinra received FDA approval for treating moderate to severe plaque psoriasis, showcasing strong efficacy and safety profiles [22]. -礼来’s three-target agonist for type 2 diabetes achieved significant results in a Phase III trial, with participants experiencing an average A1C reduction of 2.0% and weight loss of 36.6 pounds [23]. Company Dynamics -沃森生物's controlling shareholder changed to 腾云新沃, which will hold a significant stake in the company following a stock issuance [26]. - Collegium announced the acquisition of AZSTARYS for $650 million, with potential additional payments based on future milestones [27]. IPO Dynamics - Upcoming IPOs include 德适-B and 同仁堂医养, both scheduled for March 30, 2026 [28].